Human Ubiquitin/Ubiquitin+1 Alexa Fluor® 350-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: Ubiquitin

Ubiquitin+1 has a carboxyl terminal amino acid sequence that differs from normal Ubiquitin. The different carboxyl terminal sequence appears to result from a frameshift in the Ubiquitin mRNA. The underlying mechanisms creating the mRNA frameshift are not clearly understood. The occurrence of the frameshift that generates Ubiquitin+1 is much more prevalent in patients with Alzheimers Disease or with Down Syndrome than in control individuals who are not afflicted with the disorders. The monoclonal anti-Ubiquitin+1 (Catalog # MAB703) and rabbit polyclonal anti-Ubiquitin+1 (Catalog # AF703) antibodies were raised against the Ubiquitin+1 carboxyl terminal sequence that differs from normal Ubiquitin and are therefore non-reactive with Ubiquitin. Monoclonal anti-Ubiquitin (Catalog # MAB701) detects both Ubiquitin and Ubiquitin+1 indicating that the epitope recognized by this antibody is contained in the portion of the proteins that are identical.

Product Datasheets

Related Research Areas

• Cell Structure and Signaling Molecules
• Cell to Cell Adhesion Disassembly During EMT
• HIF Transcription Factors
• Negative Regulators of the Jak/STAT Pathway
• Neurofibrillary Tangle Formation
• NFkB Pathway
• Notch Pathway
• Parkinson's Disease Related Molecules
• Ubiquitin
• Ubiquitin-related Molecules in the Akt Pathway
• Wnt Intracellular Signaling